Energenesis Biomedical CO.,LTD. (6657.TW)

TWD 58.3

(2.1%)

Operating Expenses Summary of Energenesis Biomedical CO.,LTD.

  • Energenesis Biomedical CO.,LTD.'s latest annual operating expenses in 2023 was 267.06 Million TWD , down -3.52% from previous year.
  • Energenesis Biomedical CO.,LTD.'s latest quarterly operating expenses in 2024 Q2 was 55.39 Million TWD , down -97.8% from previous quarter.
  • Energenesis Biomedical CO.,LTD. reported a annual operating expenses of 276.81 Million TWD in annual operating expenses 2022, up 117.2% from previous year.
  • Energenesis Biomedical CO.,LTD. reported a annual operating expenses of 127.44 Million TWD in annual operating expenses 2021, down -7.92% from previous year.
  • Energenesis Biomedical CO.,LTD. reported a quarterly operating expenses of 55.95 Million TWD for 2024 Q1, down -4.17% from previous quarter.
  • Energenesis Biomedical CO.,LTD. reported a quarterly operating expenses of 58.9 Million TWD for 2023 Q1, up 22.45% from previous quarter.

Annual Operating Expenses Chart of Energenesis Biomedical CO.,LTD. (2023 - 2019)

Historical Annual Operating Expenses of Energenesis Biomedical CO.,LTD. (2023 - 2019)

Year Operating Expenses Operating Expenses Growth
2023 267.06 Million TWD -3.52%
2022 276.81 Million TWD 117.2%
2021 127.44 Million TWD -7.92%
2020 138.41 Million TWD -11.9%
2019 157.1 Million TWD 0.0%

Peer Operating Expenses Comparison of Energenesis Biomedical CO.,LTD.

Name Operating Expenses Operating Expenses Difference
Apex Biotechnology Corp. 389.4 Million TWD 31.417%
Sinphar Pharmaceutical Co.,Ltd. 807.86 Million TWD 66.942%
Panion & Bf Biotech Inc. 817.56 Million TWD 67.334%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 437.58 Million TWD 38.968%
GenMont Biotech Incorporation 204.2 Million TWD -30.783%
Abnova (Taiwan) Corporation 126.72 Million TWD -110.75%
Adimmune Corporation 1.13 Billion TWD 76.443%
Tanvex BioPharma, Inc. 2.16 Billion TWD 87.639%
Polaris Group -3.06 Million TWD 8813.344%
UnicoCell Biomed Co., Ltd. 17.89 Million TWD -1392.228%
PELL Bio-Med Technology Co. Ltd. 385.1 Million TWD 30.652%